{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:13:44Z","timestamp":1790615624569,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jaad.2018.12.018","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T11:46:34Z","timestamp":1545133594000},"page":"1590-1598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["TNF-\u03b1 inhibitor\u2013induced psoriasis: A\u00a0decade of experience at the Cleveland Clinic"],"prefix":"10.1016","volume":"83","author":[{"given":"Sean E.","family":"Mazloom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery Z.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Ya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elaine","family":"Husni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.12.018_bib1","first-page":"2287","article-title":"Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series","volume":"30","author":"Jarrett","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?","volume":"62","author":"Baeten","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2018.12.018_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00128071-200607040-00006","article-title":"The role of antimalarials in the exacerbation of psoriasis: a systematic review","volume":"7","author":"Herman","year":"2006","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib4","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2018.12.018_bib5","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","article-title":"Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study","volume":"22","author":"Guerra","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2018.12.018_bib6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1097\/MIB.0b013e31828075bd","article-title":"Tumor necrosis factor alpha antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system","volume":"19","author":"Kip","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2018.12.018_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2018.12.018_bib8","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2018.12.018_bib9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2018.12.018_bib10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.crohns.2012.08.007","article-title":"Induction or exacerbation of psoriatic lesions during anti-TNF-alpha therapy for inflammatory bowel disease: a systematic literature review based on 222 cases","volume":"7","author":"Denadai","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaad.2018.12.018_bib11","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jaad.2011.05.038","article-title":"Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: the Mayo Clinic experience, 1998 to 2010","volume":"67","author":"Shmidt","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib14","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/ajg.2015.205","article-title":"Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience","volume":"110","author":"Freling","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2018.12.018_bib15","first-page":"700","article-title":"Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?","volume":"30","author":"Joyau","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/RHU.0b013e3182a702e8","article-title":"Psoriasiform reactions to anti-tumor necrosis factor alpha therapy","volume":"19","author":"Nguyen","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib17","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2018.12.018_bib18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2018.12.018_bib19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2005.07.024","article-title":"The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking","volume":"54","author":"Michaelsson","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/000155502320624069","article-title":"Palmoplantar pustulosis: an autoimmune disease precipitated by smoking?","volume":"82","author":"Hagforsen","year":"2002","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2018.12.018_bib21","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1525-1470.2011.01521.x","article-title":"Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children","volume":"29","author":"Perman","year":"2012","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.12.018_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/pde.13081","article-title":"Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents","volume":"34","author":"Eickstaedt","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/11532060-000000000-00000","article-title":"Inverse psoriasis: case presentation and review","volume":"12","author":"Syed","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1586\/egh.12.64","article-title":"Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents","volume":"7","author":"Guerra","year":"2013","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib25","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2010.07.022","article-title":"Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy","volume":"8","author":"Rahier","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib26","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series","volume":"34","author":"Cohen","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.crohns.2011.10.007","article-title":"Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases","volume":"6","author":"Guerra","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaad.2018.12.018_bib28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/039463200902200126","article-title":"Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis","volume":"22","author":"Bruzzese","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jaad.2018.12.018_bib29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archdermatol.2011.275","article-title":"Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases","volume":"147","author":"Chu","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10067-007-0789-5","article-title":"Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine","volume":"27","author":"Aslanidis","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/1346-8138.13803","article-title":"Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy","volume":"45","author":"Suh","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jdcr.2015.05.007","article-title":"Infliximab treatment-induced paradoxical psoriasiform reaction in patient with psoriasis vulgaris showing positive lymphocyte transportation test reaction","volume":"1","author":"Ishii-Osai","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2018.12.018_bib33","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/abd1806-4841.20164456","article-title":"Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis","volume":"91","author":"Vasconcellos","year":"2016","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.jaad.2018.12.018_bib34","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1365-2036.2012.05082.x","article-title":"Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease","volume":"35","author":"Buisson","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2018.12.018_bib35","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2036.2009.03955.x","article-title":"Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease","volume":"29","author":"Fiorino","year":"2009","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218330895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218330895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:54:56Z","timestamp":1759272896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218330895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0190962218330895"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.12.018","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TNF-\u03b1 inhibitor\u2013induced psoriasis: A\u00a0decade of experience at the Cleveland Clinic","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}